- Home
- BBIO vs DD Comparison
BBIO vs DD Comparison
Compare BBIO & DD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | DD |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 18.7B |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BBIO | DD |
|---|---|---|
| Price | $74.24 | $131.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 25 | 12 |
| Target Price | ★ $86.33 | $56.67 |
| AVG Volume (30 Days) | ★ 1.9M | 828.6K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.79% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.22 |
| Revenue | $502,076,000.00 | ★ $20,397,000,000.00 |
| Revenue This Year | $89.45 | $6.72 |
| Revenue Next Year | $73.78 | $3.83 |
| P/E Ratio | ★ N/A | $59.10 |
| Revenue Growth | ★ 126.26 | N/A |
| 52 Week Low | $48.78 | $33.34 |
| 52 Week High | $93.42 | $149.42 |
Technical Indicators
Market Signals| Indicator | BBIO | DD |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | 40.53 |
| Support Level | $70.65 | $131.09 |
| Resistance Level | $75.91 | $143.42 |
| Average True Range (ATR) | 2.16 | 2.91 |
| MACD | -0.80 | -1.84 |
| Stochastic Oscillator | 3.10 | 2.58 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About DD DuPont de Nemours Inc.
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the healthcare, water, construction, automotive, aerospace, and printing and packaging industries. Healthcare and water will generate the majority of profits.